mevrometostat (PF-06821497) / Pfizer 
Welcome,         Profile    Billing    Logout  

4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
mevrometostat (PF-06821497) / Pfizer
MEVPRO-1, NCT06551324: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer ().

Not yet recruiting
3
600
Japan, US
PF-06821497, EZH2i, Docetaxel, Taxotere, Enzalutamide, XTANDI
Pfizer
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
12/25
10/28
NCT05767905: A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.

Completed
1
18
US
PF-06821497 Treatment A, PF-06821497 Treatment B, PF-06821497 Treatment C, PF-06821497 Treatment D, PF-06821497 Treatment E, PF-06821497 Treatment F
Pfizer
Healthy
06/23
06/23
NCT06392230: A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body.

Not yet recruiting
1
6
Europe
Oral [14C] PF-06821497, Oral PF-06821497, IV [14C] PF-06821497
Pfizer
Healthy Participants
11/24
11/24
NCT03460977: Mevrometostat Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Recruiting
1
343
Europe, Japan, US, RoW
Mervometostat (PF-06821497), EZH2i, Enzalutamide, Xtandi
Pfizer
Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
12/25
12/25

Download Options